New Mount Sinai discovery maps cell growth processes useful for future cancer drug development
Researchers at Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute have made a new discovery regarding how normal cells communicate and control their growth. The novel findings have the potential to better inform the selection of cancer drug therapies in clinical trials, and to improve drug resistance in cancer patients.
Published in the prestigious journal Nature today, researchers in Dr. Anthony Pawson’s lab at the Lunenfeld-Tanenbaum Research Institute studied a cell growth trigger that is initiated by a protein which is often mutated in cancer. This protein, called epithelial growth factor receptor (EGFR), sits on the cell surface, and sends signals inside cells to control processes such as cell survival and expansion. The protein is an important target for cancer drug therapies.
Using targeted mass spectrometry, a cutting-edge technology, scientists in Dr. Pawson’s lab tracked the assembly of multiple proteins into signaling complexes from the moment the EGFR signal is turned ‘on’, to when the cell signal turns ‘off’. In cancer, the ‘off’ signal is often defective, leading to uncontrolled cell growth.
Entry filed under: Biotechnology News and Info from Canadian Universities. Tags: Canadian Science, cancer research.